Unitree prices IPO at $9 billion, China's first listed humanoid robot maker

Unitree's $9.04 billion IPO valuation marks a watershed moment for Chinese robotics: the company becomes the first domestically-listed humanoid robot manufacturer at a time when the global robotics sector is attracting significant capital and talent. The timing is notable because 2025 saw Unitree's revenue more than quadruple and its humanoid robot segment—which generated 867.8 million yuan in sales—overtake its previously dominant quadruped robot business, demonstrating genuine market traction rather than speculative positioning.

Yet the valuation also highlights the gap between commercialized robotics and speculative estimates. At $9 billion, Unitree trades at a substantial discount to analyst projections for Tesla's Optimus (Bank of America: $30 billion; Morgan Stanley: up to $180 billion), even though Tesla's humanoid robot has not yet reached mass production. The difference is stark: Unitree has shipped units and generated measurable revenue, while Optimus remains in pilot deployment. This gap suggests either that the market discounts Unitree's scaling ability or that analyst estimates for Optimus embed significant optionality and future-production assumptions.

The backdrop is deteriorating US-China technology relations. The US introduced new restrictions last month that could prevent future foreign-produced humanoid robots from obtaining sale approvals, though Unitree's existing products remain authorized. With the US generating 13.3 percent of Unitree's 2025 revenue, regulatory risk is real but not yet prohibitive. Unitree's first-quarter 2026 profit fell 52.6 percent despite revenue growth, a warning that the path to scale profitably while defending market share against well-funded competitors—particularly Tesla—remains uncharted.